38678-59-0

Basic information

• Product Name: L-Leucinamide, L-phenylalanyl-
• CAS NO: 38678-59-0
• Molecular Formula: C15H23N3O2
• Molecular Weight: 277.367
• Mol File: 38678-59-0.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: L-Leucinamide, L-phenylalanyl-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Leucinamide, L-phenylalanyl-(38678-59-0)
• EPA Substance Registry System: L-Leucinamide, L-phenylalanyl-(38678-59-0)

Safety Data

• Hazardous Substances Data: 38678-59-0(Hazardous Substances Data)

Upstream product

• 65118-58-3 N-Ac-L-Phe-L-Leu-NH₂ 
• 687-51-4 H-L-Leu-NH₂ 
• 2577-90-4 methyl (2S)-2-amino-3-phenylpropanoate 
• 2666-93-5 (S)-Leu-OMe 
• 13734-34-4 N-tert-butoxycarbonyl-L-phenylalanine 
• 74257-73-1 tert-butyl ((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate 
• 32909-56-1 Nα-pivaloyl-L-phenylalanine 
• 108395-58-0 acetyl L-phenylalanine chloroethyl ester 
• 10466-61-2 (2S)-amino-4-methylpentanamide hydrochloride 
• 3397-32-8 N-(benzyloxycarbonyl)-phenylalanine-N-hydroxysuccinimide ester 
• 35909-92-3 N-carbobenzoxy-L-phenylalanine methyl ester 
• 69193-13-1 Cbz-L-Phe-L-Leu-NH₂ 
• 3081-24-1 H-Phe-OEt 

Downstream Products

• 81638-88-2 amide of N-t-butyloxycarbonyl-O-benzyl-L-tyrosylglycylglycyl-L-phenylalanyl-L-leucine 
• 138850-05-2 Boc-Met-Leu-Phe-Phe-Leu-NH₂ 
• 132910-39-5 (S)-2-[(S)-2-(2-{2-[(S)-2-Acetylamino-3-(4-hydroxy-phenyl)-propionylamino]-acetylamino}-acetylamino)-3-phenyl-propionylamino]-4-methyl-pentanoic acid amide 
• 85574-42-1 Z-Tyr(Z)-(D)Ala-Gly-Phe-Leu-NH₂ 
• 3303-55-7 L-Phe-Leu 
• 126028-19-1 N-cbz-L-Phe-L-Phe-L-Leu-NH₂ 
• 69193-15-3 N-(benzyloxycarbonyl)-glycyl-L-phenylalanyl-L-leucine amide 
• 71591-21-4 Z-Tyr-Gly-Gly-Phe-Leu-NH₂ 
• 1161-13-3 N-Cbz-L-Phe 
• 65189-64-2 H-Tyr-D-Ala-Gly-Phe-Leu-NH₂ 

Relevant articles and documents

Mapping the s1 and s1’ subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents

The cysteine protease cruzipain is considered to be a validated target for therapeutic intervention in the treatment of Chagas disease. A series of 26 new compounds were designed, synthesized, and tested against the recombinant cruzain (Cz) to map its S1/S1′ subsites. The same series was evaluated on a panel of four human cysteine proteases (CatB, CatK, CatL, CatS) and Leishmania mexicana CPB, which is a potential target for the treatment of cutaneous leishmaniasis. The synthesized compounds are dipeptidyl nitriles designed based on the most promising combinations of different moieties in P1 (ten), P2 (six), and P3 (four different building blocks). Eight compounds exhibited a Ki smaller than 20.0 nM for Cz, whereas three compounds met these criteria for LmCPB. Three inhibitors had an EC50 value of ca. 4.0 μM, thus being equipotent to benznidazole according to the antitrypanosomal effects. Our mapping approach and the respective structure-activity relationships provide insights into the specific ligand-target interactions for therapeutically relevant cysteine proteases.

The application of modified α-chymotrypsin to peptide synthesis in frozen aqueous systems

-

Enzymatic Synthesis of Short Peptides in Heterogeneous Mixtures of Substrates

-